High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Posttraumatic Stress Disorder
Conditions
Posttraumatic Stress Disorder
Trial Timeline
Feb 7, 2017 → Mar 22, 2019
NCT ID
NCT02517424About High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis
High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis is a phase 2 stage product being developed by Tilray for Posttraumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02517424. Target conditions include Posttraumatic Stress Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02517424 | Phase 2 | Completed |
Competing Products
8 competing products in Posttraumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Adjunctive asenapine | Merck | Approved | 85 |
| sertraline (Zoloft) | Pfizer | Pre-clinical | 22 |
| Ziprasidone | Pfizer | Approved | 84 |
| Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg | Brain Biotech | Phase 2 | 44 |
| Riluzole | Brain Biotech | Phase 1 | 25 |